Elevated serum CD44 level is associated with unfavorable outcome in non- Hodgkin's lymphoma

Blood

Volumn 90, Issue 10, 1997, Pages 4039-4045

  Ristamäki, Raija ^a   Joensuu, Heikki ^b   Lappalainen, Kimmo ^b   Teerenhovi, Lasse ^b   Jalkanen, Sirpa ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HERMES ANTIGEN; LACTATE DEHYDROGENASE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOLUMINESCENCE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0343273084     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.10.4039     Document Type: Article

References (33)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987, 1993
2. Lopez Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343, 1994
3. Hermans J, Krol ADG, VanGroningen K, Kluin PM, Kluinnelemans JC, Kramer MHH, Noordijk EM, Ong F, Wijermans PW: International prognostic index for aggressive non-Hodgkins lymphoma is valid for all malignancy grades. Blood 86:1460, 1995
4. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC: Lymphocyte recognition of high endothelium: Antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal. or synovial endothelial cells. J Cell Biol 105:983, 1987
5. Brown TA, Bouchard T, St.John T, Wayner E, Carter WG: Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 113:207, 1991
6. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160, 1992
7. Jalkanen S, Jalkanen M, Bargatze R, Tammi M, Butcher EC: Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 141:1615, 1988
8. Jalkanen ST, Bargatze RF, Herron LR, Butcher EC: A lymphoid cell surface giycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 16:1195, 1986
9. Picker LJ, Nakache M, Butcher EC: Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 109:927, 1989
10. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 54:271, 1993
11. Haynes BF, Telen MJ, Hale LP, Denning SM: CD44 - A molecule involved in leukocyte adherence and T-cell activation. Immunol Today 10:423, 1989
12. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW: Monoclonal antibodies to Pgp-1/CD44 block lymphohemopoiesis in long-term bone marrow cultures. J Exp Med 171:477, 1990
13. Koopman G, van Kooyk Y, de Graaff M, Meyer CJ, Figdor CG, Pals ST: Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 145:3589, 1990
14. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A: CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128:687, 1995
15. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13, 1991
16. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53:4754, 1993
17. Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG: Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53:5345, 1993
18. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615, 1995
19. Jalkanen S, Joensuu H, Söderström KO, Klemi P: Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 87:1835, 1991
20. Ristamäki R, Joensuu H, Söderström KO, Jalkanen S: CD44v6 expression in non-Hodgkin's lymphoma: An association with low histological grade and poor prognosis. J Pathol 176:259, 1995
21. Stauder R, Eisterer W, Thaler J, Gunthert U: CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 85:2885, 1995
22. Ristamäki R, Joensuu H, Salmi M, Jalkanen S: Serum CD44 in malignant lymphoma: An association with treatment response. Blood 84:238, 1994
23. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54:422, 1994
24. Ristamäki R, Joensuu H, Grön-Virta K, Salmi M, Jalkanen S: Origin and function of circulating CD44 in non-Hodgkin's lymphoma. J Immunol 158:3000, 1997
25. Bazil V, Horejsi V: Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J Immunol 149:747, 1992
26. Katoh S, McCarthy JB, Kincade PW: Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J Immunol 153:3440, 1994
27. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112, 1982
28. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860, 1971
29. 7 integrins, and L-selectin. J Neuropathol Exp Neurol 56:557, 1997
30. Dalchau R, Kirkley J, Fabre JW: Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. Eur J Immunol 10:745, 1980
31. Ellims PH, Eng Gan T, Medley G, Van Der Weyden MB: Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 58:926, 1981
32. Swann F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F: A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518, 1989
33. Sarris AH, Majlis A, Dimopoulos MA, Younes A, Swann F, Rodriguez MA, McLaughlin P, Cabanillas F: Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Leuk Lymphoma 17:473, 1995